

LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W

WX0000003826 F 12/05/1988 34 Y

Referral Testing						
	Collected: 0	8/28/2023	3 14:40	Received	: 08/28/2023	14:40
<u>Test Name</u>	Result	Flag	Ref-Ranges		<u>Units</u>	<u>Site</u>
TP53 Somatic Mutation, Prognostic						
Specimen Type	BLOOD					QCRL
Block Number	N/A					QCRL
P53 Mutation, Leumeta						QCRL
Exon 4						QCRL
Exon 5						QCRL
Exon 6						QCRL
Exon 7						QCRL
Exon 8						QCRL
Exon 9						QCRL
Interpretation	NOT DETECTED					QCRL

Based on sequence analysis, no clinically significant mutations were detected in the TP53 gene exons 2-11 (all coding region).

Mutations in TP53 tumor suppressor gene occur in greater than 50% of adult human cancers. The TP53 gene mutations usually correlate with poor outcome and early recurrence in cancer. Testing was performed on P53 exon 2-11 which account for >90% mutations in TP53 gene. We cannot rule out the possibilities of mutation in other sites of the gene.

The total nucleic acid was extracted from patient's whole blood or bone marrow cells or paraffin embedded tissues. For paraffin embedded specimens, microscopic review and marking of the specimen was performed by a pathologist, and genomic DNA was extracted from macro-dissected paraffin-embedded tissue sections. Next-generation sequencing (NGS) was used to detect mutations in all coding exons of TP53 (exons 2-11). TP53, NM_000546.5 was used as reference. This assay does not detect large deletions in the p53 gene. For (17p-) please refer to FISH assay. The sensitivity of this sequencing assay is 5% of mutant alleles in the background of normal wildtype alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Laboratory results and submitted clinical information reviewed by Bernard Joseph Ilagan, MD, MHA, FACMG, CGMBS.



LABORATORY REPORT

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W**WX0000003826 F 12/05/1988 34 Y

Performing Site:

QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675

Reported Date: 2023.08.28 14:43 TP53